Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet wh
Simply Wall StApr 26 10:35 ET
Bio-Rad Laboratories: Executive Transition and Shareholder Decisions
TipRanksApr 26 08:44 ET
Bio-Rad Announces Life Science Group Management Changes
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced the promotion of James J. Barry, currently Senior Vice President of Global
BusinesswireApr 26 08:30 ET
Express News | Shares of Life Sciences Tools Stocks Are Trading Higher Following Strong Earnings From Danaher
Moomoo 24/7Apr 23 09:58 ET
Danaher Gains as Q1 Results Exceed Expectations
Seeking AlphaApr 23 06:58 ET
Express News | Bio-Rad Laboratories Inc Reports 8.99% Passive Stake In Oncocyte Corp As Of April 15, 2024
Moomoo 24/7Apr 22 13:35 ET
Express News | Bio-Rad Laboratories Inc Reports 8.99% Passive Stake in OncoCyte Corp as of April 15 - SEC Filing
Moomoo 24/7Apr 22 13:31 ET
Goldman's Debt Issuers Stocks Basket
Seeking AlphaApr 22 12:53 ET
Analyzing The Notable After-Hour Surge In Bio-Rad Laboratories (BIO) Stock
Bio-Rad Laboratories, Inc. (NYSE: BIO) has experienced a notable surge in its stock valuation during the extended trading period, witnessing a substantial uptick of 13.40% to achieve a value of $1,281.51. Bio-Rad stock value surged on the US stock charts after the company unveiled the release date of its financial results. Bio-Rad (BIO) is intending ...
Stocks TelegraphApr 22 04:01 ET
Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
Business WireApr 18 09:00 ET
Bio-Rad Laboratories (NYSE:BIO Shareholders Incur Further Losses as Stock Declines 14% This Week, Taking Three-year Losses to 53%
Yahoo FinanceApr 17 08:43 ET
Express News | OncoCyte Shares Jump 46% Premarket After Co's Partnership With Bio-Rad
Moomoo 24/7Apr 12 04:44 ET
Oncocyte Stock Rallies 90% Post-market on Bio-Rad Partnership
Seeking AlphaApr 11 18:15 ET
Express News | OncoCyte Corp - Bio-Rad and OncoCyte Will Co-Market Assay Inside US and Germany, With OncoCyte Acting as Commercial Lead
Moomoo 24/7Apr 11 17:32 ET
Express News | OncoCyte Corp - Bio-Rad Expects to Make Equity Investment in Support of Deal
Moomoo 24/7Apr 11 17:31 ET
Express News | OncoCyte Corp - Bio-Rad Has Been Granted an Option for Ivd Commercial Rights at FDA Clearance, Subject to Meeting Specific Objectives
Moomoo 24/7Apr 11 17:30 ET
Express News | OncoCyte and Bio-Rad Partner on Global Launch of Transplant Assay
Moomoo 24/7Apr 11 17:30 ET
Bio-Rad Laboratories On Pace for Largest Percent Decrease Since October 2023 -- Data Talk
Bio-Rad Laboratories, Inc. Class A (BIO) is currently at $318.64, down $12.46 or 3.76% --Would be lowest close since Feb. 13, 2024, when it closed at $316.10 --On pace for largest percent decrease s
Dow JonesApr 11 10:49 ET
Cardinal Health, Cigna, Merck Among Top Healthcare Quant Picks Ahead of Q1 Earnings
Seeking AlphaApr 11 10:33 ET
Bio-Rad Laboratories: Last Will Remain Part of Exec Leadership Team to Ensure Smooth Transition During Search for His Successor >BIO
Bio-Rad Laboratories: Last Will Remain Part of Exec Leadership Team to Ensure Smooth Transition During Search for His Successor >BIO
Dow JonesApr 10 16:16 ET
No Data
No Data